RIO-LIPIDS研究PPT课件.pptVIP

Rimonabant in Obesity RIO LIPIDS Trial RIO LIPIDS Trial RIO LIPIDS Trial Among patients with abdominal obesity and abnormal lipid profiles, use of the selective cannabinoid type 1 receptor antagonist rimonabant in a 5 mg or 20 mg dose was associated with greater weight reduction after 1 year of treatment compared with placebo Additional benefits were observed in HDL and triglyceride levels with rimonabant Obesity is a growing epidemic, which has been shown to contribute to a variety of co-morbidities, including increased coronary heart disease, diabetes, and hyperlipidemia Few pharmaco